Conflicts of interest
Takeda/Millennium, Muscular Dystrophy
NEUROMUSCULAR DISEASES, MUSCULAR DYSTROPHY
This study was sponsored by argenx SE, the manufacturer of efgartigimod alfa, which is approved for use in patients with AChR-Ab+ generalized myasthenia gravis by the US Food and Drug Administration. Sihui Zhao, PhD; Deborah Gelinas, MD; Cynthia Z. Qi; Silvia Chiroli, MD; and Glenn Phillips, PhD, are employees of argenx. Silvia Chiroli, MD, is a stock shareholder in addition to being an employee of argenx. Francesco Saccà, MD, has received honoraria for public speaking from Alexion, Biogen, Mylan, Novartis, Roche, Sanofi, and Teva; served on advisory boards for Alexion, Almirall, argenx, AveXis, Biogen, Forward Pharma, Lexeo Therapeutics, Merck, Novartis, Roche, Sanofi, and Takeda; and served as clinical trial principal investigator for Alexion, argenx, Novartis, Prilenia, and Sanofi. Carolina Barnett, MD, PhD, has received grant support from the US Department of Defense, US National Institutes of Health, Muscular Dystrophy Canada, MGNet, Grifols, and Octapharma. She has participated in advisory boards for Alexion, Sanofi, and argenx and been a consultant for CSL, Alexion, and argenx. Jan J.G.M. Verschuuren, MD, has received grant support from the Prinses Beatrix Spierfonds, Health Holland and participated in consultancies for argenx, Alexion, Ra Pharmaceuticals, and NMD Pharma. Reimbursements were received by the Leiden University Medical Centre. He is co-inventor on patent applications based on MuSK-related research. He is a member of the European Reference Network for Rare Neuromuscular Diseases. Stojan Peric, MD, PhD, served as site principal investigator for MG clinical trials sponsored by argenx, Ra/UCB, and Takeda/Millennium and is a consultant for argenx. Tuan Vu, MD, served as site principal investigator for MG clinical trials sponsored by Alexion, argenx, Ra/UCB, Horizon/Viela Bio, Janssen/Momenta, Regeneron, and Cartesian Therapeutics and is a consultant for UCB, Alexion, and argenx.